Alvotech (ALVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alvotech (ALVO) has a cash flow conversion efficiency ratio of 0.314x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Ikr-55.58 Million ≈ $-453.08K USD) by net assets (Ikr-176.76 Million ≈ $-1.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alvotech balance sheet quality to measure how much of total assets are equity-financed.
Alvotech - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Alvotech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Alvotech earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Alvotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alvotech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Tongrun Equipment Technology Co Ltd
SHE:002150
|
0.003x |
|
MCEWEN MINING INC.
F:US8
|
0.006x |
|
Oriental Holdings Bhd
KLSE:4006
|
0.060x |
|
Xiamen Wanli Stone Stock Co Ltd
SHE:002785
|
0.275x |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
0.017x |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
0.044x |
|
Hunan Fazhan Industrial Co Ltd
SHE:000722
|
0.032x |
|
Suzhou Shihua New Material Technology Co Ltd
SHG:688093
|
0.030x |
Annual Cash Flow Conversion Efficiency for Alvotech (2020–2024)
The table below shows the annual cash flow conversion efficiency of Alvotech from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see ALVO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Ikr-412.77 Million ≈ $-3.37 Million |
Ikr-236.84 Million ≈ $-1.93 Million |
0.574x | +71.39% |
| 2023-12-31 | Ikr-932.49 Million ≈ $-7.60 Million |
Ikr-312.19 Million ≈ $-2.55 Million |
0.335x | -39.51% |
| 2022-12-31 | Ikr-564.42 Million ≈ $-4.60 Million |
Ikr-312.39 Million ≈ $-2.55 Million |
0.553x | -67.10% |
| 2021-12-31 | Ikr-135.61 Million ≈ $-1.11 Million |
Ikr-228.17 Million ≈ $-1.86 Million |
1.683x | +1864.00% |
| 2020-12-31 | Ikr-867.24 Million ≈ $-7.07 Million |
Ikr-74.30 Million ≈ $-605.70K |
0.086x | -- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more